Ichthyosis Follicularis, Atrichia, and Photophobia (IFAP) Syndrome, Type 2: Clinical Case
https://doi.org/10.15690/vsp.v23i3.2759
Abstract
Background. Ichthyosis follicularis with atrichia and photophobia (IFAP syndrome), type 2 is a rare hereditary disease from the group of syndromic forms of ichthyosis. It is clinically characterized by triad of non-inflammatory follicular ichthyosis, total or subtotal alopecia at birth or shortly after, and photophobia of different severity. There is no etiotropic therapy for IFAP syndrome, while symptomatic treatment (emollients, keratolytics, retinoids) is aimed on stabilizing the patient’s condition and maintaining the optimal quality of life. About 60 cases of IFAP syndrome have been described worldwide by 2023, and none in Russia.
Clinical case description. The girl, 2 years 3 months old, had signs of xeroderma, follicular hyperkeratosis, photophobia with lacrimation, and alopecia. The diagnosis of “ichthyosis follicularis with atrichia and photophobia (IFAP syndrome), type 2, autosomal dominant” was established according to anamnesis, clinical signs, and results of whole-exome sequencing, followed by validation of the identified nucleotide variant chr17:17720597G>A, p.1669C>T (p.Arg557Cys NM_001005291.2) in exon 9 of the SREBF1 gene via direct automatic sequencing in the patient and both parents (not revealed in her parents).
Conclusion. Molecular genetic testing is crucial to establish IFAP syndrome as clinical signs of the disease are similar to other dermatoses. However, physicians need to have clinical suspicion when identifying cases of follicular ichthyosis in combination with alopecia and photophobia at or shortly after birth to timely diagnose IFAP syndrome and thus prevent any treatment delays.
Keywords
About the Authors
Eduard T. AmbarchyanRussian Federation
Moscow
Disclosure of interest:
receiving research grants from pharmaceutical companies Eli Lilly, Novartis, AbbVie, Pfizer, Amryt Pharma plc, scientific consultant of Johnson & Johnson
Anastasiya D. Kuzminova
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests
Totuy K. Eldarova
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests
Vladislav V. Ivanchikov
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests
Nataliya V. Zhurkova
Russian Federation
Moscow
Disclosure of interest:
lecturing for pharmaceutical companies Takeda, Sanofi Aventis Group, AstraZeneca, Chiesi pharmaceuticals, Nutricia
Nato D. Vashakmadze
Russian Federation
Moscow
Disclosure of interest:
lecturing for pharmaceutical companies Takeda, Sanofi Aventis Group, Biomarin, Nanolek, Chiesi pharmaceuticals, Nutricia, AstraZeneca
References
1. Saat H, Sahin I, Duzkale N, et al. Genetic etiology of ichthyosis in Turkish patients: Next-generation sequencing identified seven novel mutations. Medeni Med J. 2022;37(2):126–130. https://doi.org/10.4274/mmj.galenos.2022.39924
2. Ikhtioz u detei: clinical guidelines. Union of Pediatricians of Russia; 2016. p. 6. (In Russ).
3. Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: Results of the first Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol. 2010;63(4):607–641. https://doi.org/10.1016/j.jaad.2009.11.020
4. Mazereeuw-Hautier J, Vahlquist A, Traupe H, et al. Management of Congenital ichthyoses: European guidelines of care, part one. Br J Dermatol. 2018;180(2):272–281. https://doi.org/10.1111/bjd.17203
5. McLeod JM. Three cases of ‘ichthyosis follicularis’ associated with baldness. Br J Dermatol. 1909;21:165–189.
6. Wang H, Humbatova A, Liu Y, et al. Mutations in SREBF1, Encoding Sterol Regulatory Element Binding Transcription Factor 1, Cause Autosomal-Dominant IFAP Syndrome. Am J Hum Genet. 2020;107(1):34–45. https://doi.org/10.1016/j.ajhg.2020.05.006
7. Morice-Picard F, Michaud V, Lasseaux E, et al. Hereditary Mucoepithelial Dysplasia Results from Heterozygous Variants at p.Arg557 Mutational Hotspot in SREBF1, Encoding a Transcription Factor Involved in Cholesterol Homeostasis. J Invest Dermatol. 2020;140(6):1289–1292.e2. https://doi.org/10.1016/j.jid.2019.10.014
8. Chacon-Camacho OF, Arce-Gonzalez R, Ordaz-Robles T, et al. Exome sequencing identifies a SREBF1 recurrent ARG557CYS mutation as the cause of hereditary mucoepithelial dysplasia in a family with high clinical variability. Am J Med Genet A. 2020;182(11):2773–2777. https://doi.org/10.1002/ajmg.a.61849
9. Migliavacca MP, Fock RA, Almeida N, et al. A Brazilian case of IFAP syndrome with severe congenital ichthyosis and limb malformations caused by a rare variant in MBTPS2. Rev Paul Pediatr. 2023;41:e2022057. https://doi.org/10.1590/1984-0462/2023/41/2022057
10. Okutman O, Muller J, Baert Y, et al. Exome sequencing reveals a nonsense mutation in TEX15 causing spermatogenic failure in a Turkish family. Hum Mol Genet. 2015;24(19):5581–5588. https://doi.org/10.1093/hmg/ddv290
11. Mao L, Wang Y, An L, et al. Molecular Mechanisms and Clinical Phenotypes of GJB2 Missense Variants. Biology (Basel). 2023;12(4):505. https://doi.org/10.3390/biology12040505
12. Irurzun I, Natale MI, Agostinelli ML, et. al. Ichthyosis follicularis, atrichia and photophobia (IFAP) and hereditary mucoepithelial dysplasia: Two syndromes that share a common clinical spectrum. Pediatr Dermatol. 2021;38(3):568–574. https://doi.org/10.1111/pde.14560
13. Nagakeerthana S, Rangaraj M, Karthikeyan K. Ichthyosis Follicularis, Alopecia, and Photophobia Syndrome. Int J Trichology. 2017;9(2):67–69. https://doi.org/10.4103/ijt.ijt_69_16
14. Mégarbané H, Mégarbané A. Ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome. Orphanet J Rare Dis. 2011;6:29. https://doi.org/10.1186/1750-1172-6-29
15. Traboulsi E, Waked N, Mégarbané H, Mégarbané A. Ocular findings in ichthyosis follicularis-alopecia-photophobia (IFAP) syndrome. Ophthalmic Genet. 2004;25(2):153–156. https://doi.org/10.1080/13816810490514405
16. Höpker LM, Ribeiro CG, Oliveira LM, Moreira AT. Ichthyosis follicularis, alopecia and photophobia syndrome (IFAP): report of the first case with ocular and cutaneous manifestations in Brazil with a favorable response to treatment. Arq Bras Oftalmol. 2011;74(1):55–57. https://doi.org/10.1590/s0004-27492011000100013
17. Cursiefen C, Schlötzer-Schrehardt U, Holbach LM, et al. Ocular findings in ichthyosis follicularis, atrichia, and photophobia syndrome. Arch Ophthalmol. 1999;117(5):681–684. https://doi.org/10.1001/archopht.117.5.681
18. Basilious A, Fung SSM, Ali A. Limbal Stem Cell Dysfunction in Ichthyosis Follicularis, Alopecia, and Photophobia Syndrome. Cornea. 2020;39(10):1321–1324. https://doi.org/10.1097/ICO.0000000000002393
19. Cammarata-Scalisi F, Willoughby CE, Cárdenas Tadich A, et al. Clinical, etiopathogenic, and therapeutic aspects of KID syndrome. Dermatol Ther. 2020;33(4):e13507. https://doi.org/10.1111/dth.13507
20. Rajesh S, Loganathan E, Shanmukhappa AG. Ichthyosis Follicularis with Alopecia and Photophobia Syndrome with Coexisting Palmoplantar Keratoderma Treated with Acitretin. Int J Trichology. 2022;14(6):213–215. https://doi.org/10.4103/ijt.ijt_9_22
Review
For citations:
Ambarchyan E.T., Kuzminova A.D., Eldarova T.K., Ivanchikov V.V., Zhurkova N.V., Vashakmadze N.D. Ichthyosis Follicularis, Atrichia, and Photophobia (IFAP) Syndrome, Type 2: Clinical Case. Current Pediatrics. 2024;23(3):181-187. (In Russ.) https://doi.org/10.15690/vsp.v23i3.2759